학술논문

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
Document Type
Article
Source
In Annals of Oncology April 2020 31(4):507-516
Subject
Early drug development
Language
ISSN
0923-7534